Plasma miRNA marker for diagnosis of lung cancer and application

Abstract

The invention belongs to the biotechnical field and relates to a plasma miRNA marker for diagnosis of lung cancer and application. The invention provides the plasma miRNA marker for diagnosis of lung cancer. The marker comprises miRNA-486, miRNA-150, miRNA-205 and miRNA-210. The invention further provides primer probes shown in sequences SEQ ID NO. 1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4 as well as application of the primer probes in preparation of kits for diagnosis of lung cancer. The marker provided by the invention has the beneficial effects that a biomarker which has a relatively high diagnostic value on lung cancer is found, and the biomarker has a relatively high diagnostic value (AUC is 0.975, and the sensitivity and specificity are respectively 90.9% and 100%).

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to a plasma miRNA marker for lung cancer diagnosis and its application. Background technique [0002] Lung cancer is currently one of the most common and deadliest malignant tumors in the world, and it is also the largest cancer in my country, with the fastest growing incidence and mortality. Due to the insidious onset of lung cancer, its diagnosis and treatment are far from satisfactory, mainly due to the lack of early diagnosis means and effective treatment methods. Most of the patients are in advanced stage when symptoms appear, and the prognosis is poor. The overall five-year survival rate is less than 15%, and the symptomatic patients are ≤10%. However, for patients with lung cancer diagnosed at an early stage, the prognosis of surgical treatment is significantly improved compared with that of advanced lung cancer, and the survival rate can reach 70%. It can be seen that in order t...

AI Technical Summary

Problems solved by technology

[0004] Due to the diversity of lung cancer histopathology, the heterogeneity of tumor cells of the same pathology, and the complexity and polymorphism of tumor biological behavior, the diagnostic value of single marker detection for lung cancer is limited, and it can only reflect some aspects of the disease Many scholars at home and abroad tend to screen a variety of valuable tumor markers for joint detection in order to increase the positive rate of lung cancer diagnosis

Although it has become a consensus that combined detection is better than single detection, not any combination can improve the positive rate of clinical diagnosis, and the conclusions on the best combination are quite inconsistent, and even the opposite results

Images